Modasmart 400mg (Modafinil Tablets)

Description

Understanding the 400mg Strength

Modasmart 400mg is presented as a branded product labelled as containing modafinil at a 400mg strength. The labelled product strength should not be confused with an appropriate prescribed dose: a 400mg-labelled tablet does not by itself establish that 400mg should be taken as a single dose, taken daily or used by every patient.

A higher labelled milligram strength does not automatically provide greater clinical benefit. Modafinil treatment should be individualised according to the diagnosed condition, medical history, treatment response and other relevant clinical factors.

General prescribing information for registered modafinil products may discuss total daily doses in particular clinical circumstances, but that information does not establish a Modasmart 400mg dosing regimen, an Australian-approved 400mg tablet regimen or instructions to take 400mg at one time.

Understanding Modasmart 400mg

The product discussed on this page, Modasmart 400mg, is presented as being labelled with modafinil at a strength of 400mg. Because independently verified primary product documentation has not been established here, that product description should not be interpreted as independent confirmation of composition, manufacturing arrangements or Australian regulatory status.

Modafinil is a wakefulness-promoting medicine used in recognised clinical contexts involving excessive daytime sleepiness. Its medical evidence should be considered separately from the exact regulatory or product status of the Modasmart finished product.

The appropriate treatment regimen must be determined by an appropriately qualified healthcare professional. A labelled 400mg strength should never be used on its own to select a dose, frequency or treatment duration.

About the Active Ingredient

Modafinil is a centrally acting wakefulness-promoting medicine. Although its precise mechanism remains incompletely understood, research indicates that it influences neurotransmitter and neural systems involved in maintaining wakefulness, including dopamine-related and other signalling pathways.

These findings concern modafinil as an active pharmaceutical ingredient and should not be interpreted as Modasmart-specific clinical evidence.

For related educational context on the distinction between a branded finished product and modafinil as the active ingredient, see Modvigil 200mg vs Modafinil. Modvigil and Modasmart are separate branded products, and shared ingredient claims do not establish bioequivalence, interchangeability or identical regulatory status.

Recognised Medical Uses

Modafinil is used in recognised medical settings involving excessive daytime sleepiness, including narcolepsy, obstructive sleep apnoea where appropriate primary treatment remains important, and shift work sleep disorder in suitably assessed patients.

For obstructive sleep apnoea, wakefulness-promoting treatment addresses excessive sleepiness rather than the underlying airway obstruction. Appropriate primary management, including CPAP where prescribed or recommended, should continue.

These uses relate to modafinil and relevant clinical or registered-product evidence. They do not establish Australian-approved indications or ARTG registration for Modasmart 400mg.

For broader ingredient-level educational context, see Modvigil 200mg uses, benefits and side effects.

Before Starting Treatment

Before modafinil treatment begins, tell your healthcare professional about relevant medical conditions, including cardiovascular disease, high blood pressure, liver or kidney problems and significant mental health conditions. A history of substance misuse and all prescription medicines, over-the-counter medicines and supplements should also be discussed.

Pregnancy requires particular caution. Australian regulatory information for the registered modafinil product MODAVIGIL was updated to include pregnancy in its contraindications and to strengthen information about fetal harm, congenital malformations and spontaneous abortion. The TGA provides updated pregnancy safety information for modafinil.

This regulatory information concerns MODAVIGIL and should not be represented as Modasmart Product Information. Anyone who is pregnant, planning pregnancy or becomes pregnant while receiving modafinil should seek medical advice promptly.

People who are breastfeeding or planning to breastfeed should also discuss modafinil treatment with their healthcare professional. Pregnancy safety information should not automatically be assumed to provide identical breastfeeding guidance.

Taking the Medicine

Modasmart 400mg should only be used according to the instructions provided by the prescribing healthcare professional and valid product-specific labelling supplied with the medicine.

The labelled 400mg product strength does not establish how much should be taken, whether a dose should be taken at one time or divided, how frequently treatment should be used, or how long treatment should continue.

General modafinil administration information from other registered products should not be treated as verified Modasmart-specific instructions.

If a dose is missed, follow the directions provided by the prescriber, pharmacist or valid product-specific medicine information rather than independently changing the dosing schedule.

Possible Side Effects

Modafinil can cause side effects. Reported effects include headache, nausea, nervousness or anxiety, dizziness, difficulty sleeping and gastrointestinal symptoms. Individual experiences vary.

Serious reactions have also been reported with modafinil, including severe skin reactions, serious hypersensitivity reactions, cardiovascular symptoms and significant psychiatric or behavioural changes.

Seek prompt medical attention for serious or unexpected symptoms such as a severe or spreading rash, facial or throat swelling, difficulty breathing, chest pain, hallucinations, suicidal thoughts or marked behavioural changes.

These safety statements relate to modafinil evidence and should not be interpreted as independent Modasmart-specific pharmacovigilance data.

For broader ingredient-level safety information, see Modvigil 200mg side effects.

Medicine Interactions

Modafinil may interact with other medicines and can affect the way some treatments are metabolised. Potentially relevant interactions include certain anticoagulants, anti-epileptic medicines, antidepressants, hormonal contraceptives and other medicines affected by liver-enzyme pathways.

Interaction risks depend on the medicines involved and individual clinical circumstances. Patients should provide their healthcare professional or pharmacist with a complete list of prescription medicines, over-the-counter products, vitamins, herbal products and supplements.

Hormonal Contraception

Modafinil can interact with hormonal contraception and may reduce the effectiveness of some hormonal contraceptive methods.

People using hormonal contraception should obtain individual contraceptive advice from an appropriately qualified healthcare professional rather than relying on general product information.

Practical Precautions

An underlying sleep disorder can itself impair alertness, and individual responses to modafinil treatment vary. Patients should understand how both their condition and treatment affect them before driving, operating machinery or performing other safety-sensitive activities.

Regular medical review remains important during treatment. New or worsening symptoms should be reported promptly, and healthcare professionals should be informed before significant treatment changes or new medicines are introduced.

Alcohol use should be discussed with a healthcare professional rather than assuming that a specific interaction applies to every individual.

Storage

• Follow the storage instructions provided on the supplied product packaging or label.
• Keep the medicine in its supplied packaging where appropriate.
• Keep medicines out of sight and reach of children.
• Do not use the product after the expiry date shown on the packaging.

Exact Modasmart 400mg storage conditions should be taken from valid product-specific information rather than inferred from general medicine-storage guidance.

Responsible Use

Modafinil is a prescription-only medicine in Australia. This ingredient-level prescription status does not establish that the Modasmart finished product is ARTG registered or has Australian-approved indications.

Responsible use of Modasmart 400mg means following professional medical advice, avoiding unauthorised dose changes, not sharing prescription medicines and attending recommended medical reviews. The 400mg labelled strength should not be self-selected on the assumption that a higher strength will provide greater benefit.

Adequate sleep and appropriate management of the underlying sleep disorder remain important during wakefulness-promoting treatment.

Frequently Asked Questions

What is Modasmart 400mg?

Modasmart 400mg is presented as a branded tablet labelled as containing modafinil at a 400mg strength. This description does not establish Australian ARTG registration, Australian-approved indications or a particular approved dosing regimen for the product.

Is 400mg the usual dose of modafinil?

Not necessarily. Product strength and prescribed dose are different concepts.

Australian prescribing information for particular registered modafinil products may discuss total daily doses up to 400mg in some clinical contexts, but this does not establish that a 400mg single dose, one 400mg tablet or a Modasmart 400mg regimen is appropriate for an individual patient.

A healthcare professional should determine the dose, frequency and treatment schedule.

How long does Modasmart take to start working?

There is no single verified Modasmart-specific onset time that applies to everyone. Pharmacokinetic timing, first perceived effects, duration of wakefulness-related effects and assessment of longer-term clinical response are different concepts.

For broader educational discussion of these timing concepts, see how long Modvigil 200mg takes to work. That article concerns a separate branded product and should not be interpreted as evidence of Modasmart-specific onset, identical pharmacokinetics or bioequivalence.

Is it safe to drive while receiving modafinil treatment?

An underlying sleep disorder may continue to impair alertness, and individual responses to modafinil vary. Patients should understand how both their condition and treatment affect them before driving, operating machinery or performing safety-sensitive tasks.

Does Modasmart 400mg require a prescription in Australia?

Modafinil is a Schedule 4 Prescription Only Medicine in Australia. This scheduling status applies to modafinil and does not itself establish ARTG registration or Australian-approved indications for the Modasmart finished product.

Medical Disclaimer

This information about Modasmart 400mg is provided for general educational purposes only. It does not replace personalised medical advice, diagnosis or treatment and should not be used to self-diagnose, self-select a medicine or choose the 400mg strength.

Modafinil is a Schedule 4 Prescription Only Medicine in Australia. Treatment decisions, including the appropriate product, strength, dose and treatment schedule, require assessment by an appropriately qualified healthcare professional.

Australian clinical, prescribing and regulatory information concerning modafinil or other registered modafinil products does not establish that the Modasmart finished product is ARTG registered, has Australian-approved indications or has an Australian-approved 400mg dosing regimen.

Additional Information